坦度螺酮在综合医院治疗患者焦虑状态临床应用的专家建议  

Expert advice on the treatment of anxiety with tandospirone in general hospitals

作　　者：中国医药卫生文化协会心身医学研究分会 赵靖平[2] 陆峥[3] Psychosomatic Medicine Research Branch of China Health Culture Association;Zhao Jingping(Department of Psychiatric Discipline, the Second Xiangya Hospital of Central South University, Changsha 410008, China)

机构地区：[1]不详 [2]中南大学湘雅二医院精神病学科,长沙410008 [3]同济大学附属同济医院

出　　处：《中国医药》2019年第6期935-939,共5页China Medicine

摘　　要：坦度螺酮是5-羟色胺1A部分激动剂,2003年在中国上市,一系列上市前后的临床研究,尤其是基于我国人群的临床研究,为坦度螺酮的临床应用提供了循证证据。为进一步优化坦度螺酮在综合医院焦虑状态治疗的应用,在综合近年循证证据及临床实践经验的基础上撰写了本文,以期对坦度螺酮的规范化用药起到一定的指导作用。Tandospirone, a kind of 5-hydroxytryptamine 1A receptor partial agonist, was marketed in China in 2003. A series of clinical researches before and after listed, especially the data based on Chinese population, provided evidence for the application of tandospirone. In order to optimize the practical use of tandospirone in treatment of anxiety in general hospitals, and improve the prognosis of patients, expert advice on the treatment of anxiety in general hospitals with tandospirone is presented here. This advice is based on the recent evidence and clinical experience to guide the clinical medication of tandospirone.

关 键 词：焦虑 坦度螺酮 5-羟色胺1A部分激动剂 

分 类 号：R749.7[医药卫生—神经病学与精神病学]